Walter Lajara-Nanson, MD
Neurology · Great Falls, MTNPI 1528050283
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (41.9%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 21 manufacturers reported payments, led by AbbVie at 41.6% of the total. Reporting peaked in 2019 at $1,919 and has fallen 73.9% since, to $501 in 2025.
Across 87 payments — averaging $63.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Livanova USA, Inc.$2K
- Merz Pharmaceuticals, LLC$382
- TG Therapeutics, Inc.$161
- Sanofi$90
- Teva Pharmaceuticals USA, Inc.$84
- plus $473 from 15 others
What the payments were for
- Speaking & faculty fees$1,75032%
- Travel & lodging$1,37425%
- Food & beverage$2,31342%
- Education$852%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 30 | $2,299 |
| Livanova USA, Inc. | 15 | $2,033 |
| Merz Pharmaceuticals, LLC | 9 | $382 |
| TG Therapeutics, Inc. | 4 | $161 |
| Sanofi | 1 | $90 |
| Teva Pharmaceuticals USA, Inc. | 2 | $84 |
| Argenx US, Inc. | 3 | $66 |
| Biogen | 2 | $64 |
| Acadia Pharmaceuticals Inc | 3 | $53 |
| Sunovion Pharmaceuticals Inc. | 4 | $44 |
| CSL Behring | 2 | $40 |
| Lundbeck LLC | 2 | $38 |
| Eisai Inc. | 2 | $33 |
| Johnson & Johnson | 1 | $26 |
| Neurelis, Inc. | 1 | $23 |
| Medtronic | 1 | $21 |
| Lilly USA, LLC | 1 | $15 |
| Genentech USA, Inc. | 1 | $15 |
| AstraZeneca | 1 | $13 |
| Pfizer | 1 | $12 |
| Aucta Pharmaceuticals, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Duopa$1,750
- VNS Therapy$1,501
- VNS THERAPY SENTIVA MODEL 1000 GENERATOR$319
How this compares
$5,522 in reported general payments places this provider in the 75th percentile of 48 neurology providers in Montana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Kesimpta PenOfatumumab | 28 | $251,588 |
| NuplazidPimavanserin Tartrate | 26 | $126,681 |
| IngrezzaValbenazine Tosylate | 11 | $85,378 |
| RytaryCarbidopa/Levodopa | 77 | $74,505 |
| GocovriAmantadine Hcl | 23 | $56,533 |
| NuedextaDextromethorphan Hbr/Quinidine | 29 | $46,008 |
| Tetrabenazine | 16 | $16,904 |
| Dalfampridine ErDalfampridine | 36 | $11,190 |
| Ajovy AutoinjectorFremanezumab-Vfrm | 15 | $10,160 |
| Lacosamide | 134 | $9,899 |
| Aimovig AutoinjectorErenumab-Aooe | 13 | $9,331 |
| Emgality PenGalcanezumab-Gnlm | 12 | $8,429 |
| TrintellixVortioxetine Hydrobromide | 17 | $8,134 |
| Selegiline Hcl | 64 | $8,110 |
| Rivastigmine | 35 | $6,533 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Acadia Pharmaceuticals IncNuplazid | $53 | $126,68126 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 48 neurology providers in Montana.
Other neurology in Great Falls
- Dennis DietrichGreat Falls$140K
- Deborah DoverGreat Falls$19K
- Eliad CulceaGreat Falls$19K
- William HenningGreat Falls$4K
- Cody SandersGreat Falls$1K
- Ann CollierBillings$164K
- Nicole ClarkHelena$85K
- Kristian FrenchBillings$64K
- Norman FriedmanKalispell$35K
- Emily PharrBozeman$14K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.